Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06731426 · ClinicalTrials.gov registry record · NA
Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion
A NA study of OCD, sponsored by Han Joo Lee.
- Recruiting
- Registry status
- NA
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT06731426: Recruiting NA study of OCD, sponsored by Han Joo Lee.
NCT06731426 is a NA study of OCD that is actively recruiting participants, run by Han Joo Lee. The registered enrollment target is 84 participants, below the 813-participant average among 18 other OCD trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06731426, a NA study of OCD, is actively recruiting participants, sponsored by Han Joo Lee.
- RECRUITING
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Thought-Action-Fusion (TAF) is a cognitive bias that posits (1) having unwanted thoughts is morally equivalent to acting upon the thoughts (TAF-Moral; e.g., "Thinking about harming a child is as immoral as actually harming a child") and (2) having unwanted thoughts will increase the likelihood of the thoughts happening in real life (TAF-Likelihood; e.g., "My mother will get into a car accident, because I thought about it"). Given its central role in the development and maintenance of OCD, TAF has emerged as a potential treatment target for obsessive-compulsive disorder (OCD). Previous research has demonstrated that TAF is indeed a malleable construct. This study aims to examine the effects of a multi-session, personalized cognitive bias modification (CBM) for thought-action-fusion (TAF) on improving obsessive-compulsive (OC) symptoms in a college sample.
Primary Outcome
The Thought-Action-Fusion Scale (TAFS; Shafran et al., 1996) is a 19-item measure, which assesses the presence and severity of TAF among adults. The measure uses a 5-point Likert scale, which ranges from 0 (Disagree Strongly) to 4 (Agree Strongly) with 12 items assessing TAF-moral, 3 items assessing TAF-likelihood-self, and 4 items assessing TAF-likelihood-others. The measure generates three scores (TAF-total, TAF-Moral, TAF-likelihood) and higher scores indicate higher severity.
Conditions Studied
Interventions
- BEHAVIORAL CBM-TAF
- BEHAVIORAL CBM-SMP
Study Locations (1)
Wisconsin
- UWM Anxiety Disorders Laboratory - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2024-04-18 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
What NCT06731426 shows while recruiting
NCT06731426 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 813-participant average among 18 other OCD trials with a reported enrollment target (90% lower).
The record links to 1 condition, with OCD appearing as the primary indexed condition, and to 2 interventions - of which CBM-TAF is the first listed.
NCT06731426 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06731426 about?
NCT06731426 is a clinical study titled "Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion". Thought-Action-Fusion (TAF) is a cognitive bias that posits (1) having unwanted thoughts is morally equivalent to acting upon the thoughts (TAF-Moral; e.g., "Thinking about harming a child is as immoral as actually harming a child") and (2) having unwanted thoughts will increase the likelihood of th...
What is the current status of trial NCT06731426?
This trial is currently recruiting. It is a NA study. The enrollment target is 84 participants. The study started on 2024-04-18. Estimated completion is 2026-05-31.
What conditions does trial NCT06731426 study?
This clinical trial studies the following conditions: OCD.
What interventions are being tested in trial NCT06731426?
The interventions under investigation include: CBM-TAF (BEHAVIORAL), CBM-SMP (BEHAVIORAL).
Who is sponsoring clinical trial NCT06731426?
This trial is sponsored by Han Joo Lee, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06731426 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OCD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06731426's enrollment target sits among peer trials
84 10th of 18 higher than 9 of 18 other OCD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other OCD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation for a Novel OCD Biomarker and Treatment
RECRUITING · NA
-
Personalized DBS for OCD Guided by Stereoencephalography Mapping
RECRUITING · NA
-
Neurostimulation Versus Therapy for Problems With Emotions
RECRUITING · NA
-
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
RECRUITING · NA
-
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
RECRUITING · NA
-
Accelerated TMS for Depression and OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI